Alpine Associates Management Inc. Grows Stock Holdings in CureVac N.V. $CVAC

Alpine Associates Management Inc. grew its holdings in CureVac N.V. (NASDAQ:CVAC) by 16.4% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,295,422 shares of the company’s stock after buying an additional 324,247 shares during the period. CureVac makes up 0.7% of Alpine Associates Management Inc.’s portfolio, making the stock its 27th largest holding. Alpine Associates Management Inc. owned approximately 1.02% of CureVac worth $12,372,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CureVac by 354.8% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 5,608 shares of the company’s stock valued at $30,000 after acquiring an additional 4,375 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of CureVac during the 2nd quarter valued at approximately $35,000. Integrated Wealth Concepts LLC raised its holdings in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock valued at $42,000 after buying an additional 3,000 shares during the period. L2 Asset Management LLC bought a new stake in CureVac in the second quarter worth $70,000. Finally, Gabelli Funds LLC bought a new stake in CureVac in the second quarter worth $130,000. 17.26% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CureVac in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $6.83.

CureVac Price Performance

Shares of NASDAQ CVAC opened at $4.66 on Thursday. CureVac N.V. has a 52-week low of $4.00 and a 52-week high of $4.68. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 6.47 and a beta of 1.77. The stock has a 50 day moving average price of $4.65 and a 200 day moving average price of $5.11. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.69 and a current ratio of 3.70.

CureVac (NASDAQ:CVAC) last issued its earnings results on Monday, November 24th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.07. The business had revenue of $63.53 million during the quarter, compared to analysts’ expectations of $21.40 million. CureVac had a negative return on equity of 23.03% and a net margin of 199.92%. Sell-side analysts expect that CureVac N.V. will post 0.72 earnings per share for the current year.

CureVac Company Profile

CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs.